Gut Microbiome Study
(PRIMM – Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics.)
There is increasing evidence that the population of bugs that live in our guts, the gut microbiome, can profoundly influence how our immune system responds to cancer. PRIMM is an international, collaborative study led by Dr Nathan, a consultant dermatologist Dr Dr.Veronique Bataille and Professor Tim Spector at King’s College. Together they are looking at the influence of the gut microbiome on the effectiveness and toxicity of immunotherapy in melanoma patients.
CTRT supports a research fellow, Karla Loudon, and a research assistant, Simran Sumal on the PRIMM study. Karla has registered for her PhD and is doing excellent work on the association between microbiome and outcomes in the PRIMM cohort. The study has a high international impact and major publications are starting to be delivered.